Vivoryon Therapeutics ( VVY ), DKD new therapeutic target has been confirmed… Improved eGFR raises expectations for new drug development↑

Vivoryon Therapeutics (VVY) has presented new evidence for a diabetes kidney disease (DKD) treatment target, enhancing expectations for its pipeline expansion. This analysis, published at the 2026 World Congress of Nephrology, emphasizes that “glutamyl cyclase” inhibition may play a significant role in protecting kidney function.

On March 28 (local time), Vivoryon Therapeutics announced at the congress that after re-analyzing data from its Phase 2 clinical projects VIVIAD and VIVA-MIND, it consistently confirmed the improvement effects on estimated glomerular filtration rate (eGFR). Particularly, the effects were more pronounced in older patients with diabetes, raising attention to its potential in delaying disease progression.

Similar results were also confirmed in animal models. In experiments with diabetic kidney disease mice, improvements in kidney function indicators were observed, reinforcing the association with clinical data in “translational research.” The company explained that this further demonstrates that glutamyl cyclase is a promising target for DKD treatment.

This result also adds momentum to the development strategy for Vivoryon’s main candidate “varoglutamstat.” The company is considering the possibility of expanding indications from diabetic patients to later-stage chronic kidney disease patient populations. The industry believes that the emergence of treatment drugs based on new mechanisms in the DKD market, where current treatment options are limited, could meaningfully change the competitive landscape.

Comments: A research leader from a global pharmaceutical company remarked, “Diabetes kidney disease itself is an important area for inhibiting disease progression,” and noted, “If eGFR improvement is repeatedly confirmed, it is likely to become a positive signal in subsequent clinical trials.”

Vivoryon Therapeutics plans to enhance data credibility through the design of future additional clinical trials and aims to enter the later development stage. This publication suggests the possibility of a paradigm shift in the treatment of “diabetes kidney disease,” which is expected to accelerate competition in the development of related new drugs.